- Home
- DERM vs ANTX Comparison
DERM vs ANTX Comparison
Compare DERM & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DERM | ANTX |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.3M | 129.8M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | DERM | ANTX |
|---|---|---|
| Price | $5.02 | $4.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $12.67 | $2.00 |
| AVG Volume (30 Days) | 187.9K | ★ 334.8K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.72 | 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,858,000.00 | N/A |
| Revenue This Year | $39.72 | N/A |
| Revenue Next Year | $63.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.20 | N/A |
| 52 Week Low | $4.31 | $1.00 |
| 52 Week High | $9.56 | $6.91 |
Technical Indicators
Market Signals| Indicator | DERM | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.37 | 70.62 |
| Support Level | $4.31 | $1.06 |
| Resistance Level | $5.60 | $6.91 |
| Average True Range (ATR) | 0.26 | 0.36 |
| MACD | 0.10 | 0.13 |
| Stochastic Oscillator | 15.71 | 81.23 |
Price Performance
Historical ComparisonAbout DERM Journey Medical Corporation
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.